This is what I know from discussions with the business
Neo is going along really well and Vascucel is finally getting traction after somewhat of a false start which WP mentioned in Feb. 3D is by far and away the most premium priced product and will drive revenue considerably going forward.
TAVR is progressing via IP filings which is an ongoing process....the next major announcement around TAVR will likely be a deal indications of deal discussions....time frame unknown.
They are involved in a few hospital tenders but have no visibility on the likelihood of success.
The fate of immunotherapies was not up for discussion as it is price sensitive. Read into that what you will.
Cheers
This is what I know from discussions with the business Neo is...
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.56 |
Change
-0.740(5.56%) |
Mkt cap ! $265.4M | |||
| Open | High | Low | Value | Volume |
| $13.06 | $13.30 | $12.55 | $359.0K | 27.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 399 | $12.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.78 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |